ãã€ãªå»è¬åäŒæ¥ã® Hoth Therapeutics, Inc. ã¯ãç®èçŸæ£ã®æ²»çæ³ã®éçºã«æ³šåããŠããŸããå瀟ã¯ã湿ç¹ãæ
¢æ§åµå·ã也ç¬ã忝ãããããªã©ã®çç¶ã«èŠããæ£è
ã®æ²»çæ³ã«éç¹ã眮ããŠããŸãããã€ãã©ã€ã³ ããŒããã©ãªãªã«ã¯ãããã·ã³ãããŒãŒé»å®³å€/äžç®æé·å ååå®¹äœ (EGFR) é»å®³å€çæ³ã®ååããã³å埩ã³ãŒã¹ã«é¢é£ãã軜床ããäžç床ã®çºç¹ããã³ç®èçŸæ£ã®æ²»çã®ããã®å±æè£œå€ HT-001ãSARS-CoV-2 ææã«é¢é£ããçŸæ£ãæ²»çããããã® HT-002ããããããã³ä¹Ÿç¬ã®å±ææ²»ççš HT-003Dãççæ§è
žçŸæ£ãæ²»çããããã® HT-003IBã忝ãã¢ãããŒæ§ç®èçããã®ä»ã®ã¢ã¬ã«ã®ãŒçŸæ£ãæ²»çããããã® HT-004ãç®èãšãªããããŒãã¹ãæ²»çããããã® HT-005 Z-PODS ãå«ãŸããŸããå瀟ã¯ãè€æ°ã®çްèç
åäœã®æ²»çè¬ã§ããHT-006ãéçºããŠããŸããå瀟ã¯ããžã§ãŒãžã»ã¯ã·ã³ãã³å€§åŠãã¡ãªãŒã©ã³ã倧åŠãã€ãœãã¬ã³ã»ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€ŸãããŒã¹ã«ãã©ã€ãå·ç«å€§åŠãã·ã§ã¬ã¯ãµã»ãã€ãªãµã€ãšã³ã¹ç€Ÿãã·ã³ã·ããã£å€§åŠãšã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸãããŸããZylö Therapeuticsç€Ÿãšææºå¥çŽãçµã³ãç®èã«åœ±é¿ãåãŒãæ£è
ã®ç掻ã®è³ªã«é倧ãªè² æ
ããããæ
¢æ§èªå·±å
ç«çŸæ£ã§ããç®èãšãªããããŒãã¹ã®æ£è
ã®ããã®æ°ããå±ææ²»çè¬ãå
±åéçºããŠããŸãããŸããWeill Cornell Medicineãšã®ç ç©¶ååå¥çŽãçµã³ããããæ²»çç ç©¶ã®ããã®HT-003ã®éçºãç¶ç¶ããŠããŸããHoth Therapeutics瀟ã¯2017幎ã«èšç«ããããã¥ãŒãšãŒã¯å·ãã¥ãŒãšãŒã¯ã«æ¬ç€Ÿã眮ããŠããŸãã